Caitlyn A. Chapman

Caitlyn A. Chapman

Auto-generated profile, based on publicly available information

Caitlyn A. Chapman

Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2019 in Materials Today Chemistry
Verified
Journal Article
Closed access
Fábio GarrudoFábio Garrudo
Fábio Garrudo
RURanodhi N. Udangawa
Ranodhi N. Udangawa
PHP.R. Hoffman
P.R. Hoffman
LSLAURA SORDINI
LAURA SORDINI
CCC.A. Chapman
C.A. Chapman
RLRobert Linhardt
Robert Linhardt

5 August 2025 in Neuropharmacology
Verified
Journal Article
Open access
CCCaitlyn A. Chapman
Caitlyn A. Chapman
NPNadya Povysheva
Nadya Povysheva
JJJon W. Johnson
Jon W. Johnson
TJTija C. Jacob
Tija C. Jacob
Benzodiazepines (BZDs) are critical sedative, anticonvulsant, and anxiolytic drugs that potentiate inhibitory GABAergic neurotransmission. However, clinical utility is hampered by drug tolerance and a hyperexcitable withdrawal syndrome characterized by neuronal excitation/inhibition (E/I) imbalance. Although enhanced excitation is implicated in BZD tolerance, the homeostatic changes to glutamatergic receptors remain undefined. Here, we report the impact of chronic (7-day) BZD treatment on excitatory synapse and NMDA receptor (NMDAR) function, expression, and subcellular localization in cortical neurons. Chronic treatment with the BZD diazepam (DZP) resulted in an increase in NMDAR-mediated miniature excitatory postsynaptic currents (mEPSCs). Confocal imaging studies revealed a DZP-induced enrichment of GluN2B-containing NMDARs at functional synapses (expressing AMPA receptors, AMPARs) while GluN2B subunit expression was otherwise unaltered. Conversely, localization of GluN2A-containing NMDARs (GluN2A-NMDARs) to functional synapses was unchanged, while GluN2A-NMDAR total protein levels and surface accumulation were enhanced. Intriguingly, we demonstrate for the first time the BZD-induced enrichment and expansion of GluN2A-NMDAR coverage at silent (AMPAR-lacking) synapses. Finally, biochemical fractionation analysis of the translation elongation protein eEF2, known to control E/I balance, detected lower levels of deactivated, phosphorylated eEF2 in the synaptic fraction of DZP-treated neurons, indicative of enhanced local translation. Collectively, our findings suggest that chronic BZD treatment triggers compensatory mechanisms which 1) enhance NMDAR function via increased GluN2B-NMDARs at functional synapses, and 2) promote the expression, surface localization, and accumulation of GluN2A-NMDARs at silent synapses, augmenting the potential for further synaptic plasticity.

5 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CCCaitlyn A. Chapman
Caitlyn A. Chapman
NPNadya Povysheva
Nadya Povysheva
TTTyler B. Tarr
Tyler B. Tarr
JNJessica L. Nuwer
Jessica L. Nuwer
Stephen MerineyStephen Meriney
Stephen Meriney
TJTija C. Jacob
Tija C. Jacob
Benzodiazepines (BZDs) are important clinical drugs with anxiolytic, anticonvulsant, and sedative effects mediated by potentiation of inhibitory GABA type A receptors (GABA A Rs). Tolerance limits the clinical utility of BZDs, yet the mechanisms underlying tolerance after chronic exposure have not been thoroughly investigated. Here, we assessed the impact of chronic (7-day) treatment with the BZD diazepam (DZP) on the dynamic plasticity and subsynaptic organization of the gephyrin scaffold and γ2 subunit-containing GABA A Rs in primary neurons. After functional confirmation of diminished BZD sensitivity, we provide the first super-resolution analysis of inhibitory nanoscale plasticity induced by chronic BZD exposure: gephyrin subsynaptic domains were smaller and the inhibitory postsynaptic area was overall diminished by DZP treatment, resulting in a condensation of synaptic γ2-GABA A Rs into smaller subsynaptic areas. Using a novel fluorescence-based in situ proximity ligation assay and biochemical fractionation analysis, the mechanism for gephyrin downregulation was revealed to be dependent on phosphorylation and protease cleavage. Accordingly, DZP treatment impaired gephyrin synaptic stability, demonstrated by live-imaging photobleaching experiments. Despite the loss of BZD sensitivity and stable synaptic gephyrin, 7-day DZP treatment did not reduce the surface or total protein levels of BZD-sensitive γ2-GABA A Rs, as shown in prior short-term BZD treatment studies. Instead, chronic DZP treatment induced an accumulation of γ2-GABA A Rs in the extrasynaptic membrane. Surprisingly, γ2-GABA A R interactions with gephyrin were also enriched extrasynaptically. An identified rise in extrasynaptically-localized gephyrin cleavage fragments may function to confine receptors away from the synapse, as supported by a decrease in extrasynaptic γ2-GABA A R mobility. Altogether, we find that chronic BZD treatment triggers several subtle converging plasticity events at inhibitory synapses which effectively restrict the synaptic renewal of BZD-sensitive GABA A Rs via mechanisms distinct from those observed with short-term treatment.